|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
07.05.26 - 22:03
|
Personalis Reports First Quarter Results and Recent Highlights (Business Wire)
|
|
|
Clinical test volume surged 258% year-over-year and 26% sequentially to 7,815 tests in Q1
Medicare coverage secured for lung cancer surveillance, providing a clear path to monetize rapidly growing clinical test volumesFREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial and operational results for the first quarter ended March 31, 2026, highlighted recent business accomplishments, and reaffirmed financial guidance for the full year 2026.
First Quarter and Recent Strategic and Operational Highlights
Secured Milestone Medicare Coverage for Lung Cancer: Received Medicare coverage approval in the first quarter for the surveillance of cancer recurrence in lung cancer patients for Stage I to III non-small cell lung cancer (NSCLC). This marks the Company's second major coverage decision in six months, alongside breast cancer.
Announced Early Access Launch of Real-Time Variant Tracker™: Launched a pioneering new featur...
|
|
|
23.04.26 - 22:03
|
Personalis to Announce First Quarter 2026 Financial Results (Business Wire)
|
|
|
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its first quarter 2026 financial results on Thursday, May 7, 2026. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights.
Interested parties may access the call by dialing 877-451-6152 for domestic callers or 201-389-0879 for international callers. The live webinar of the call may be accessed by visiting the Events section of the company's website at investors.personalis.com. A replay of the webinar will be available shortly after the conclusion of the call and will be archived on the company's website.
About Personalis, Inc.
At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care throug...
|
|
|
17.03.26 - 21:03
|
Personalis Appoints Dr. Richard Chen as President to Further Accelerate MRD Adoption (Business Wire)
|
|
|
Dr. Chen expands his leadership role to serve as President while continuing to serve as Chief Medical Officer (CMO), unifying R&D innovation with operational execution as Personalis defines the next era of ultrasensitive MRD testingFREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the promotion of Richard Chen, M.D., M.S., to the position of President. Dr. Chen will continue to serve as CMO of Personalis in addition to his new role.
The appointment comes at a critical inflection point as Personalis transitions from a pioneering R&D powerhouse into a market leader in Minimal Residual Disease (MRD) testing. Under Dr. Chen's scientific leadership, Personalis developed and accelerated adoption of the NeXT Personal® platform, which set a new industry benchmark for ultrasensitive MRD testing, detecting cancer at levels far below those previously achievable.
"Personalis is no longer just participating in the MRD market;...
|
|
|
|
|
|
|
|
|
|
|
26.02.26 - 22:03
|
Personalis Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights (Business Wire)
|
|
|
Clinical test volume surged 41% in Q4 over Q3 to 6,183 tests and full year increased nearly 400% to 16,233 tests
Secured Medicare coverage for breast and lung cancer surveillance, validating ultrasensitive MRD technology
Strong cash position of approximately $240 million provides capital for commercial expansion
Full year 2026 revenue guidance of $78 to $80 million, driven by expected growth of approximately 5x for clinical revenue
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial and operational results for the fourth quarter and full year ended December 31, 2025 and recent business highlights and provided financial guidance for the full year 2026.
Fourth Quarter and Recent Strategic and Operational Highlights
Secured Milestone Medicare Coverages for Breast & Lung Cancer: Received Medicare coverage approval in the fourth quarter for the surveillance of cancer recurrence in breast cancer patients, and also, rec...
|
|
|
12.02.26 - 22:03
|
Personalis to Announce Fourth Quarter and Full Year 2025 Financial Results (Business Wire)
|
|
|
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its fourth quarter and full year 2025 financial results on Thursday, February 26, 2026. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights.
Interested parties may access the call by dialing 877-451-6152 for domestic callers or 201-389-0879 for international callers. The live webinar of the call may be accessed by visiting the Events section of the company's website at investors.personalis.com. A replay of the webinar will be available shortly after the conclusion of the call and will be archived on the company's website.
About Personalis, Inc.
At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management...
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
